Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
- Eric L. Simpson
- , Jonathan I. Silverberg
- , Jacob P. Thyssen
- , Manuelle Viguier
- , Diamant Thaçi
- , Marjolein de Bruin-Weller
- , Stephan Weidinger
- , Gary Chan
- , Marco DiBonaventura
- , Pinaki Biswas
- , Claire Feeney
- , Christopher Koulias*
- , Michael J. Cork
*Corresponding author for this work
- Oregon Health & Science University
- Washington University in St. Louis
- Copenhagen University Hospital Bispebjerg
- Reims University Hospital
- Utrecht University
- University of Kiel
- Pfizer Inc.
- Pfizer Endocrine Care Europe
- University of Sheffield
25
Link opens in a new tab
Citations
(Scopus)